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Abstract 
The current landscape of Adverse Outcome Pathways (AOPs) provides a means of organising 
information relating to the adverse effects elicited following exposure to chemicals. As such, 
AOPs are an excellent driver for the development and application of in silico models for 
predictive toxicology allowing for the direct relationship between chemistry and adverse 
effects to be established. Information may be extracted from AOPs to support the creation 
of (quantitative) structure-activity relationships ((Q)SARs) as well as to increase confidence 
in grouping and read-across. Any part of an AOP can be linked to these various types of in 
silico models. There is, however, an emphasis on using information from known Molecular 
Initiating Events (MIEs) to create models including 2D and 3D structural alerts, SARs and 
QSARs. MIEs can be classified according to the nature of the interaction e.g. covalent 
reactivity, oxidative stress, phototoxicity, chronic receptor mediated, acute enzyme 
inhibition, unspecific, physical and other effects. Different types of MIEs require different 
approaches to their in silico modelling. Modelling Key Events and Key Event Relationships is 
useful if they represent the rate limiting step or key determinant of toxicity. Modelling of 
metabolism and chemical interactions will become part of AOP networks, which are also 
driving species-specific extrapolation and respective adaptation of models. With more 
information and data being captured, in silico approaches will increasingly support the 
application of knowledge from AOPs to build weight of evidence and support risk 
assessment, e.g. in the context of Integrated Assessment and Testing Approaches (IATAs). 
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Introduction 
As a gradual process, the toxicological testing of chemicals is undergoing a paradigm shift. 
For decades there has been a reliance on in vivo and latterly, to a more limited extent, in 
vitro testing of a chemical with the effects being recorded and used to allow for some type 
of risk assessment. The shift is towards an assessment of the (perturbation of) pathways of 
toxicity allowing for a mechanistic basis to understanding the effects of chemicals, which is 
often overlooked in the traditional testing paradigm. This has a number of advantages, not 
least in the replacement of in vivo testing with associated reduction in animal use and, in 
most cases, costs and the time involved. Advances in what is termed 21st Century Toxicology 
are developing tools and techniques that provide information on pathways (and hence 
mechanisms) that are derived from cells and cell lines more relevant to humans and other 
target species, rather than relying on the extrapolation from surrogate test species.1  
The development of the toxicological pathway concept, not least stimulated by the 2007 
National Academies of Sciences, Engineering, and Medicine report,2 has seen a growth in 
the number of assays and hence data available, e.g. those directly associated with pathways 
such as from high throughput / content assays such as Tox21 / ToxCast3 and omics4-6 or 
those that may be applied indirectly from existing in vivo and other data.7-9 These assays 
have provided an explosion in the number of pathway related data available which could 
form the basis of either strategies to predict toxicity, or be used to develop computational 
models. However, there has been no overarching means of interpreting, rationalising or 
utilising these data. As such, the Adverse Outcome Pathway (AOP) concept was developed 
in part as a response to the call for toxicology to become pathway orientated, but also to 
assist in the utilisation of data from such assays.10 
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It is appreciated that AOPs are a conceptual framework to support the prediction of toxicity, 
a full description of AOPs is not given here but is available from various authors.10-19 In 
practical terms AOPs will assist in the organisation of data, assays, mechanistic knowledge 
and models to predict toxicity within the paradigm of 21st Century Toxicology. The ability to 
use the pathway-derived data to extract further information and knowledge is one of their 
advantages, especially when they can be formalised into computational models.20-21 When 
associated with chemical structure, these models, also called in silico approaches, can 
provide a direct linkage between chemistry and adverse effect leveraging the content of the 
AOP to support the meaning and interpretation of the model.22-23  
In silico models for toxicity prediction vary from structural alerts derived from structure-
activity relationships (SARs) through to quantitative structure-activity relationships (QSARs) 
which are suitable for the prediction of potency.24 This paper explores the linkage of these 
models, as well as grouping and read-across, to AOPs. At the outset it is well acknowledged 
that AOPs can support computational modelling.21 In addition, the use of AOPs to support 
computational modelling deriving structural alerts25-28 for toxicity prediction or as part of a 
grouping strategy leading to read-across, and for QSAR development, is well established.29  
Other computational approaches, beyond the ab initio risk assessment consideration, that 
utilise and extend the AOP framework are the development of Integrated Assessment and 
Testing Approaches (IATAs).13, 18, 30-38 
 
The Links Between in Silico Models and the Different Steps of an AOP 
Figure 1 illustrates that models, or in silico approaches, may potentially be utilised at all 
stages of the AOP to provide knowledge and information (it should be noted that the 
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structure of the generic AOP shown in Figure 1 is illustrative only and many AOPs do not 
include exposure or proceed to the ecosystem level). There are many purposes to the use of 
models within the AOP framework; these include: 
 providing data and information,  
 capturing the knowledge of the AOP, and  
 extrapolation and prediction.  
Computational, or in silico, models for toxicity prediction are many and varied. The focus of 
this paper is the relationship of chemistry-based models for toxicity prediction with AOPs. 
Briefly, as discussed in more detail below, in silico models are especially useful to capture 
and predict the Molecular Initiating Event (MIE) of an AOP, such as binding to biological 
molecules or receptors, and thus predict which chemicals can potentially be associated with 
adverse effects triggered by the MIE. (Q)SARs can also model Key Events or Key Event 
Relationships further downstream in an AOP, which is relevant for toxicity prediction in 
particular if these events are rate-determining steps in an AOP. In this case biokinetic 
modelling will support the prediction of which steps in an AOP actually take place in specific 
exposure situations, and can contribute to the prediction of which target organs a chemical 
will be distributed to and the actual target organ concentrations. Modelling exposure 
related to the source and models determining e.g. oral or skin absorption or bioavailability 
as a whole, will support quantification of the effects occurring as a result of the AOP. 
Overall, a higher level of modelling, such as multiscale modelling, will be required to capture 
all elements of the AOP to link exposure to risk. Extending the consideration of  adverse 
outcomes to the individual, population or ecological models can extrapolate and predict 
adverse effects at the population or ecosystem level. 
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FIGURE 1 HERE 
Figure 2 summarises the main differences where models may drive the development of 
AOPs and vice versa. It illustrates that on one hand AOPs can support the building of 
predictive models, to base them on mechanistic information and give them relevance for 
toxicity assessment, and on the other hand, computational models can help to compile AOP 
pathways. When both robust mechanistic information and computational models for e.g. 
bioactivities are available, this will allow for the better prediction of relevant adverse effects 
or use in an IATA. As such, the ultimate aim of building models and organising mechanistic 
information within the AOP framework is to provide relevant prediction of adverse effects 
to allow for adequate chemical safety assessment. 
FIGURE 2 HERE 
It is important to also consider that there will be a cyclical process whereby models will be 
developed on the basis of a (putative) AOP which will then be refined as more information is 
passed back to the model – likewise this will assist in the refinement of the AOP. More 
broadly, the relationship between AOPs and in silico chemistry based models can be 
considered as being: 
i) models using information derived from the AOP, 
ii) models that support the use or application of information from the AOP e.g. an AOP 
being used to provide evidence for the ab initio risk assessment of a substance and build a 
mode-of-action hypothesis,39  
iii) AOPs supporting the mechanistic interpretation of a model or providing evidence to 
build a weight of evidence to support risk assessment (cf. read-across case studies).40-43  
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This paper attempts to provide an overview of the types of models that may be applied at 
different stages of the AOP, taken in the broadest context from sources to ecosystem, with 
a particular focus on the mechanistic and toxicological aspects. This paper covers the 
mechanistic aspects of the AOP, it does not consider exposure modelling, in silico models for 
the apical endpoint (e.g. traditional (Q)SARs) or ecosystem level models.   
 
Predictive Models Based on AOP-Related Mechanistic Information 
 
Models of the Molecular Initiating Event 
Information from the Molecular Initiating Event (MIE) is one of the key drivers for in silico 
models derived from an AOP.25-28 Before computational modelling approaches are 
considered, it should be recognised that there are different types of MIEs and each may 
require a different modelling approach. These have been summarised in general terms in 
Table 1, along with examples and the types of models that can be derived from the different 
types of MIE. 22, 23, 44-74 Table 1 provides by no means an exhaustive list and practitioners will 
no doubt wish to expand this according to their needs and experience. The key to 
understand why this is important is in the concept of, if the MIE is known, then a model can 
be developed for it.  
TABLE 1 HERE 
On the basis of knowledge of different types of MIEs, it is thus possible to classify AOPs with 
regard to the type of MIE. In order to illustrate the types of MIEs, Table 2 lists the citable 
AOPs (at the time of preparation of the manuscript) listed on the AOP Wiki 
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(https://aopwiki.org/)75 which is one component of the OECD-sponsored AOP Knowledge 
Base (AOP-KB, http://aopkb.org/).76 This wiki represents the central repository for all AOPs 
developed as part of the OECD AOP development effort by the Extended Advisory Group on 
Molecular Screening and Toxicogenomics. The AOP Wiki is not, of course, a complete list of 
AOPs with many others becoming available. However, what is clear from Table 2 is that the 
majority of citable AOPs on the AOP Wiki are for ǁhat is terŵed ͞ĐhroŶiĐ reĐeptor 
ŵediated͟ toǆiĐitǇ, ǁith a sŵaller Ŷuŵďer Đlassified as ďeiŶg ͞ĐoǀaleŶt reaĐtiǀitǇ͟. This is 
probably due to the AOPs being defined, at least at the start of the process of their 
compilation, around common, well-known and familiar modes of action. Table 2 was also 
supplemented by literature examples of AOPs where none were available as being citable 
from the AOP Wiki. It must be appreciated that these literature AOPs are likely to be less 
developed (in the formal sense of the AOP Wiki) at the time of writing.12, 29, 62, 67, 77-78  
TABLE 2 HERE  
It is striking from Table 1 that the majority of models derived from AOPs utilise 2-D 
approaches to capture molecular fragments responsible for toxicity. There is a rich history of 
suĐh ͞struĐtural alerts͟ aŶd their ĐoŶǀersioŶ iŶto usaďle ĐoŵputatioŶal ŵodels.20 There are 
many good reasons for this, e.g. they are easy to define and comprehend – hence aiding in 
their transparency. Technologies such as SMARTS strings have made chemistry fragments 
easy to code and be handled computationally.79 They have also been developed into a 
number of commercially and freely available expert systems. Most notable amongst the 
freely available systems is the OECD QSAR Toolbox which for some endpoints,80 e.g. skin 
sensitisation, provides a direct linkage to the AOP and the possibility to build a read-across 
argument on the basis of data from the AOP.81, 82 They are particularly suited when a 
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structural fragment drives a particular chemical and /or biological interaction e.g. covalent 
binding to DNA or proteins.44-45 The disadvantage is that 2-D structural alerts implicitly are 
not able to capture 3-D properties and configurations that are required for receptor binding. 
2-D alerts, e.g. those coded as SMARTS strings, can be extended and made more 
sophistiĐated ǁheŶ ĐoŶsidered as ͞ĐheŵotǇpes͟, i.e. alerts eǆteŶded ǁith further 
information on molecular structure such as atomic charges; these chemotypes may be 
coded in the so-called Chemical Structure Reactivity Markup Language (CSRML).3, 83 
Receptor mediated MIEs leading to toxicity are more difficult to capture in terms of models. 
However, there is a growing appreciation for the needs for such models to assist in the 
prediction of chronic toxicity. 3-D or conformationally dependent properties can, to a 
limited extent, be captured with extended SMARTs strings which represent particular 
scaffolds.22, 23 However, this is a relatively crude approach that may be suited for grouping 
and read-across but less for toxicity prediction when understanding stereoisomerism may 
be important. Chemotypes are more suitable for the capture and modelling of 3-D effects as 
they can supplement 2-D structural alerts with other properties.83 Most suited, although 
requiring the greatest level of expertise for application, are techniques derived from drug 
design e.g. molecular modelling of the receptor-ligand interaction and / or development of 
toxicophores.57-58 There are also many reported studies (beyond the scope of this paper) on 
modelling effects associated with endocrine disruption – most notably binding to the 
oestrogen receptor. As an example, the recent CERAPP project, where a large variety of 
mostly-QSAR type models were developed, demonstrates the relevance of this approach.84 
Extending the endocrine disruption paradigm, the work of Wu et al59 mapped and compiled 
known mechanisms of developmental toxicity, supporting them with data and structural 
alerts. This is a scheme which allows for the interpretation and prediction of developmental 
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toxicity rapidly, but at this time is, at best, only partially supported by AOPs. However, this 
approach maps out where development of AOPs is required.  
There are a variety of modelling approaches relating to toxicities associated with unspecific 
MIEs, i.e. where there is no single definable interaction analogous to receptor binding or 
covalent interactions. For instance, models may be based on 2-D properties associated with 
giving the molecule the capability to act in the required manner, e.g. the amine functionality 
promoting membrane accumulation leading to phospholipidosis.68,69 Alternatively, models 
may be related to the properties that govern the unspecific effect e.g. hydrophobicity being 
the determining feature for non-polar narcosis.66 
Overall, there is a need to identify the MIE and appropriate modelling techniques for it – 
this is crucial information that can be derived from an AOP. (Q)SARs should be benchmarked 
against the MIE to ensure that the modelling approach is valid for the endpoint of interest. 
Inappropriate modelling approaches run the risk of spurious and overfit models.  
 
Models of Key Events and Key Event Relationships 
As indicated in Figure 1, the modelling of key events is further along the AOP towards apical 
endpoints and may be considered more relevant and quantitative than the MIE. Models 
may be developed for data derived from assays relating to individual Key Events, these may, 
for instance, be in the form of QSARs. However, there are two distinct issues in the 
modelling of data for Key Events, namely the difficulty in obtaining such data (although 
initiatives such as ToxCast and other High Throughput Screening projects may assist here)3 
and their relevance, especially when considered in isolation from the MIE, in comparison to, 
for instance, the MIE itself. However, when relevant data are available that are founded in 
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the preceding Key Events within the AOP, the modelling of Key Events and Key Event 
Relationships may provide a more quantitative prediction of (adverse outcome) potency 
providing they are the rate limiting step. In addition, should a Key Event or Key Event 
Relationship not occur routinely following interaction with the MIE, and require further 
stimulation, e.g. another MIE or reaching a critical concentration (a Point of Departure for 
the Key Event), then models may provide more useful information than one based on the 
MIE alone. However, should the Key Event provide no more meaningful information than 
the MIE, then it may be more appropriate to model the MIE as it is more fundamental and 
likely to be more rapid and less expensive to obtain data for.  
Any models for Key Events will be similar to those for MIEs, i.e. 2-D structural alerts for 
specific molecular fragments, toxicophores for receptor interactions. However, there are 
relatively few assay data available relevant to Key Events and even fewer, if any, models. 
One good source of information has been from the Ames test and related assays for 
genotoxic carcinogenicity. The Ames test in this instance is a good surrogate for the MIE 
involving interaction with DNA but less likely to be appropriate for the later Key Events in 
this AOP. Another source of data would be for skin sensitisation where there is a well 
developed AOP13 and where the AOP has been converted into an IATA.33 Despite the 
proliferation of assays for the different stages of the AOP, with the exception of models for 
protein reactivity,49, 85 no viable models for e.g. HClat, etc have been published. Thus in silico 
models would have the potential to eventually replace assays within the IATA, but have not 
yet been fully recognised, such models would assist in hazard identification and ultimately 
risk assessment. The reliability and relevance of in silico models to predict an endpoint 
within an IATA will be increased if the models are mechanistically based and cover different 
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steps of an acknowledged AOP in the context of a consensus approach, i.e. concordant 
results with independent prediction models.  
There is also the possibility to model Key Event Relationships, such models may assist in the 
quantification and understanding of the relationship. The benefit here is that, should the 
Key Event Relationship be the rate limiting step, then a model for that specific relationship, 
which may resemble a QSAR or quantitative activity-activity relationship (QAAR), could hold 
the key to making a quantitative prediction of potency. Currently there are few, or no 
examples of (Q)SAR or QAAR models for Key Event Relationships, although some in silico 
models for Key Event Relationships are becoming available, especially in the form of 
quantitative AOPs – as described in the next section. 
Ongoing efforts to formalise relationships in AOPs through ontologies86 and to capture 
response-response relationships and corresponding data e.g. in the Effectopedia module of 
the AOP-KB (http://effectopedia.org/)87 will further support future model development in 
this area.   
 
Models Related to the Whole AOP  
It is conceivable that the ultimate aim of modelling the AOP may result in the development 
of an algorithm, or sequence of models21, to include all steps of an AOP. However, it is 
recognised that this is a long-term aspiration and will not, necessarily, be required if there is 
the possibility to predict the adverse outcome with a defined level of confidence. Currently 
there are no chemistry-based approaches i.e. (Q)SARs that attempt to describe the AOP as 
whole. In the longer term, there may be value in this as it may assist in the implementation 
of models from the AOP in the form of IATA.88, 89 However, there will be limited value going 
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beyond chemistry-based models for the MIE and possibly the rate-limiting Key Event 
Relationship. There is increasing interest in quantitative AOPs (qAOPs) which attempt to 
formalise the Key Event Relationships from the MIE to the Adverse Outcome, e.g. Conolly et 
al89 developed a qAOP that linked the inhibition of cytochrome P450 19A aromatase (the 
MIE) to population-level decreases in the fathead minnow. The qAOP itself consisted of 
three linked computational models for relevant parts of the AOP.  
A further approach that has yet to be fully applied to AOPs is that of multi-level, or multi-
scale modelling.90 These approaches attempt to derive inter-connected models for each 
component of the AOP in a manner that is representative of the overall AOP. As such it is a 
data hungry approach. These models may be fed with data from public data sources such as 
ChEMBL22,23, 91-93 and ToxCast/Tox21.94 The use of ToxCast data in this context remains an 
opportunity and a challenge, with more data and a better appreciation of how to use the 
data required.95 
 
Specific Considerations for in Silico Modelling with Regard to AOPs  
Transformations and Interaction of Chemicals  
Until now, metabolic activation has seldom been considered as part of an AOP, however it is 
necessary for chemistry-based in silico modelling (and the use of information from an in 
vitro assay) if a realistic toxicological profile is required and only the parent structure is 
available. For instance, it is important to determine if the parent molecule will be 
metabolised into a more toxic form or detoxified. A large number of in silico approaches are 
available to predict potential metabolites,96 some freely available and others commercial. 
The performance of such predictive methods is not always ideal with over-prediction of 
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metabolites being one problem, and it still being very difficult to identify stable metabolites 
and kinetics/rates of transformation being another.97 There is, however, the possibility that 
knowledge of metabolic events in AOPs may provide better knowledge to support improved 
toxicity prediction.  
Another possibility to use knowledge from AOPs to support the capture of information and 
development of in silico models is with effects such as chemical interactions. In this case, 
should a key stage of an AOP require the inhibition of an enzyme (either from the target or 
another molecule), this knowledge could be incorporated into a model. As yet, there are no 
approaches that have used the information from an AOP in this way – this is something that 
would be of immense benefit for understanding and modelling drug-drug interactions as 
well as predicting effects from combined exposure to chemicals, taking into consideration 
possible synergistic effects – even over time - which are not accounted for when evaluating 
chemicals individually.  
As AOPs naturally evolve from linear constructs to networks of inter-related effects21, 
metabolism and interactions will become integral to the development of AOP networks 
within an ontology framework, a formalised way to organise AOP knowledge and capture 
AOP relationships.86 This provides the possibility, for example, to include models for 
metabolism, particularly the ability to bind to a CYP or enzyme and the rate of binding / 
inhibition. In addition models will be required to predict relevant metabolites that may go 
elsewhere in the AOP network, or to completely independent AOPs. The other possibility is 
that knowledge of metabolism, metabolite formation and rates of formation which is 
contained within the AOP network will provide information for the models themselves, thus 
the AOP will drive the model.  
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Interspecies Relationships of Toxicity and Sensitivity 
AOPs provide a rational means to extrapolate toxicity across species. The relative similarity 
of acute aquatic potency within groups of compounds acting by a similar mechanism of 
action, especially non-polar narcosis has been known for many years98 and can be applied to 
successful QSAR development.29 Similarly, the need to take care for other mechanisms of 
action, particular those associated with species-specific metabolism99 or reactivity100 is 
important and can be related to the individual AOPs. Whilst generalist extrapolation 
approaches may work for lethal potency, more sophisticated modelling will be required for 
receptor mediated responses. Knowledge of the essential receptors in an AOP can help 
drive the extrapolation of AOPs from one species to another. Thus whilst AOPs are chemical-
agnostic, they are also species-specific and therefore can drive the adaption/applicability of 
predictive models. The web-based SeqAPASS tool is one such approach, utilising information 
on receptor homology to allow for extrapolation of effects, being wholly supported by the 
AOP.101-102  
 
Models for Exposure and Bioavailability – Adding Value to AOPs  
Whilst not strictly part of the AOP, computational models for exposure and bioavailability 
are useful for their implementation.103 These can impact at various points whilst using 
information from an AOP. Models for exposure and bioavailability also vary in their 
complexity. Another area of progress is the development of Aggregate Exposure Pathways 
which will provide information to derive models from.104 
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There are a number of SAR approaches that can be used to screen out compounds that are 
not likely to reach the site of the MIE. Very commonly used (especially as a drug design tool) 
is the Lipinski Rule of 5105 and various adaptions.106 The premise here is that a small number 
of easily calculated properties can identify compounds with low solubility which is taken as 
being indicative of poor oral absorption – thus if this is required for systemic exposure then 
risk assessment may be able to discount oral exposure as a likely route to stimulate the 
AOP. In a similar manner, Ates et al developed a small number of physico-chemical 
properties that are seen to be determinants of poor absorption through the skin.107 
There are also QSARs for effects such as bioavailability which may be used as part of the risk 
assessment process. In addition QSARs can provide an estimate of exposure following 
absorption through the skin,107-108 blood-brain barrier,109 cornea110 and various other 
membranes.96 Whilst such QSARs may be useful, to assess organ level concentrations 
following different types of exposure and doses requires the use of physiologically based 
kinetic (PBK) models.111-112  
 
AOP-Derived Models Driving Grouping and Domain Definition  
In addition to supporting models such as (Q)SARS, the information from MIEs is a key means 
of grouping compounds providing a mechanistic basis and transparency.113-114 In silico 2-D 
profilers of structural alerts, built on knowledge of MIEs have provided a means to group 
compounds for a number of adverse outcomes including skin sensitisation;79 respiratory 
sensitisation;46 phospholipidosis;68-69 mutagenicity;44, 115 hepatotoxicity;116 reproductive 
toxicity59 and testicular toxicity.117 Successful grouping allows for read-across to fill data 
gaps for these types of endpoints.  
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The MIE can also be used to define the chemical domain of an AOP through intelligent 
testing using assays derived around the MIE. For instance, the definition of mechanistically 
derived domains of reactivity, as measured by in chemico testing, has been shown to assist 
in the identification of chemical domains associated with protein reactivity, which in turn 
may be related to effects such as skin sensitisation or elevated acute toxic potency.118-119 
The value of AOPs to support read-across was demonstrated in a series of case studies.40-43 
The case studies demonstrated how the read-across hypothesis and justification were 
strengthened with knowledge of data from New Approach Methodologies (NAMs) that were 
related to the AOP. 120  
 
Conclusions and Recommendations 
 
AOPs provide a framework to organise information within the context of 21st Century 
Toxicology. As such, they are a good driver for the creation, development and application of 
in silico models to predict toxicity. Indeed, AOPs provide the direct mechanistic relevance 
and transparency that is a pre-requisite for in silico models of toxicity. The ability to be able 
to reference back to an AOP has been shown to be crucial for the justification of grouping 
and read-across and to allow for the development of IATA. As further information and data 
are captured, in silico models provide the means to create knowledge and apply it in a 
rational manner to predict toxicity.  
Currently most in silico models from AOPs are derived from the MIE. Qualitative models can 
be derived from knowledge of the MIE, in theory with limited knowledge and without many 
data to support the hypothesis e.g. an alert for skin sensitisation may be developed on the 
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basis of only a single data point if there is a clear mechanistic (i.e. organic chemistry) 
understanding. Quantitative models for the MIE, as well as for Key Events and Key Event 
Relationships require a more complete data set with information from a greater number of 
compounds covering a range of activity and properties. MIEs, in terms of modelling, can be 
classified into a number of types (see Tables 1 and 2). It is useful to classify MIEs in this 
manner. Capturing the type of MIE will allow for possibilities for modelling from an AOP to 
be identified; these could be stored in the AOP Wiki in the first instance and then 
progressed to Effectopedia as well as tools such as the OECD QSAR Toolbox. In order to 
maximise the use of information from AOPs there should be a shift to storing information on 
the MIE in a manner that could be translated into an in silico model e.g. classifying MIEs in 
tools such as Effectopedia and providing a direct linkage from there to a chemistry based 
model. Currently most in silico models derived from the MIE are based on 2-D descriptions 
of chemistry (with some notable exceptions). Most models are for MIEs associated with 
receptor binding, with covalent interactions also well represented.  
Key Events and Key Event Relationships may also prove useful for modelling, however, with 
notable exceptions such as receptor binding data and endpoint data such as those for the 
Ames assay, there is a lack of data. The laĐk of data is partiĐularlǇ aĐute for ͞iŶterŵediate͟ 
Key Events and Key Event Relationships i.e. those between the MIE and the adverse 
outcome. With increasing data becoming available in the framework of 21st Century 
Toxicology and high-throughput measurements, the data gaps may be filled in the future. 
However, they will only be useful if they represent the rate limiting step or key determinant 
of toxicity. These should form the basis of QSARs in particular as there is a desire to make 
the predictions more quantitative. The accurate prediction from chemical structure of 
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metabolites and their rates of formation have historically been very difficult; this is an area 
where improvements are required, especially as networked AOPs become a reality.   
Modelling of the whole AOPs, or qAOPs, will also require further data. At the moment a 
multitude of full chemistry-based computational models for a complete AOP seems unlikely. 
However, consideration of the AOP framework, especially as the new and / or updated tools 
become available, will both support model development and allow for the identification of 
gaps where either models or AOPs are required.  
In conclusion, ideally in silico models will ultimately allow for the complete replacement of 
toxicological testing whereby only a chemical structure is required to make a hazard and / or 
risk assessment – however we are a long way from achieving this. As the frameworks 
provided by AOPs (or whatever framework is utilised) to organise information and data 
become more sophisticated, the needs of modelling and the intimate and intricate 
relationship between the AOP and the models should not be forgotten but should be at the 
heart of AOP development and data capture.   
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Table 1. Types of MIEs with associated adverse outcomes and types and examples of appropriate modelling approaches 
Type of MIE Description Adverse Outcome Appropriate Type(s) of 
Modelling Approach(es) 
Examples of Models 
Covalent Reactivity Covalent binding of the 
compound with a 
biological macromolecule 
e.g. DNA, cellular 
membrane proteins, 
immunoproteins 
Mutagenicity, skin 
sensitisation, respiratory 
sensitisation, liver 
fibrosis, acute toxicity 
evaluated above 
baseline 
2-D structural alerts for 
specific molecular 
fragments, quantum 
chemical calculations of 
reactivity 
DNA binding;44 protein 
binding;45 respiratory 
sensitisation; 46 DFT 
calculations47-49 
Free Radical / Oxidative 
Stress 
Cellular or tissue damage 
caused by free radicals 
promoted by e.g. redox 
cycling 
Mutagenicity, tissue 
damage, aging, 
mitochondrial toxicity 
2-D structural alerts for 
specific molecular 
fragments, calculation of 
redox potential 
2-D alerts for excess 
aquatic toxicity;50-52 
mitochondrial toxicity53 
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Phototoxicity Damage caused by a 
reactive molecule or 
radical following excitation 
by UV light 
Mutagenicity, tissue 
damage, aging 
2-D structural alerts for 
specific molecular 
fragments, quantum 
chemical calculations of 
chemical stability 
2-D alerts and QSARs for 
excess aquatic 
(photo)toxicity54-56 
Chronic Receptor 
Mediated  
Stimulation or disruption 
of a normal physiological 
process, e.g. hormonal 
control, through 
(antagonistic or agonistic) 
binding (usually reversible) 
to a receptor 
Many and varied adverse 
outcomes e.g. disruption 
of endocrine function 
leading to reproductive 
impairment, cancer etc 
2-D alerts for scaffolds 
associated with binding. 
3-D toxicophores, 
receptor-ligand docking, 
molecular dynamics and 
other associated 
molecular modelling 
techniques 
2-D alerts for nuclear 
receptor binding leading 
to steatosis;22, 23, 3-D 
toxicophores for PPARγ 
binding leading to 
steatosis;57-58 2-D alerts 
and QSARs leading to 
reproductive toxicity and 
other endocrine effects59-
61 
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Acute Enzyme Inhibition  Irreversible inhibition of a 
physiological enzyme e.g. 
acetylcholinesterase. 
Rapid acute toxicity 
elevated above baseline 
2-D structural alerts for 
specific molecular 
fragments. 3-D 
toxicophores 
2-D and 3-D QSARs for 
excess aquatic toxicity as 
a result of enzyme 
inhibition62-64 
Unspecific  Unspecific events that 
occur at any relevant site 
e.g. reversible membrane 
disruption. 
Narcosis referring to 
basal cytotoxicity, 
resulting in anaesthesia 
and lethality, 
phospholipidosis leading 
to liver failure 
Relevant physico-chemical 
properties e.g. log P in 
aquatic environment, 
vapour pressure in air. 2-D 
structural alerts for 
specific molecular 
fragments 
QSARs for non-polar 
narcosis to aquatic 
species;65-67 2-D alerts for 
phosopholipidosis68-69 
Physical  Disruption of membranes 
due to the (physical / 
chemical) characteristics of 
a molecule 
Skin, eye, nasal, 
respiratory (other 
membrane) irritation 
and corrosion 
2-D structural alerts for 
specific molecular 
fragments. Measures of 
acidity / basicity; 
2-D alerts for skin / eye 
irritation / corrosion;70-71 
pH for irritation / 
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surfactant activity e.g. 
critical micelle 
concentration 
corrosion;72 QSAR for 
irritation73 
Othera Any other effect that may 
be related to promoting an 
adverse outcome e.g. 
weather, temperature or 
anthropogenic factors   
Any however usually 
associated with 
population decline 
Any relevant effect or 
property 
Climate as a stressor74 
 
aIt is acknowledged that AOPs in this category do not have a chemical interaction. This category of MIE is included in this table to enable any 
framework to categorise AOPs to be fully inclusive of all possible interactions. It should be noted that non-chemical interactions may need to 
be defined separately.   
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Table 2. Eǆaŵples of ĐurreŶtlǇ aǀailaďle AOPs Đlassified aĐĐordiŶg to the tǇpe of MIE. Where aǀailaďle ͞Đitaďle͟ AOPs froŵ the AOP Wiki 
(https://aopwiki.org/) have been used in preference to those available in the literature. 
AOP Title MIE of AOP Adverse Outcome OECD Project Number or 
Reference; AOP Wiki ID 
    
Covalent Reactivity 
    
Covalent Protein binding leading to Skin 
Sensitisation 
Covalent binding to 
immunoprotein 
Skin sensitisation OECD 1.1 
ID: 40 
Alkylation of DNA in male pre-meiotic germ cells 
leading to heritable mutations 
DNA alkylation Heritable mutations OECD 1.11 
ID: 15 
Protein Alkylation leading to liver fibrosis Protein alkylation Liver fibrosis OECD 1.14 
ID: 38 
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AFB1: Mutagenic mode-of-action leading to 
hepatocellular carcinoma 
Formation of pro-
mutagenic DNA Adducts 
Hepatocellular 
carcinoma 
OECD 1.8 
ID: 46 
    
Free Radical / Oxidative Stress 
    
No AOP currently citable on the AOP Wiki 
(although some are in draft form) or available in 
the literature 
   
    
Phototoxicity 
    
No AOP currently citable on the AOP Wiki or 
available in the literature 
   
    
Chronic Receptor Mediated 
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Inhibition of thyroperoxidase and subsequent 
adverse neurodevelopmental outcomes in 
mammals 
Inhibition of 
thyroperoxidase 
Neurodevelopmental 
outcomes 
OECD 1.10 
ID: 42 
Disruption of VEGFR signalling leading to 
developmental defects 
Inhibition of VegfR2 Developmental 
outcomes 
OECD 1.6 
ID: 43 
Sustained AhR activation leading to rodent liver 
tumours 
Binding to AhR Liver tumours OECD 1.7 
ID: 41 
Androgen receptor agonism leading to 
reproductive dysfunction 
Agonism of androgen 
receptor 
Reproductive 
dysfunction 
OECD 1.12 
ID: 23 
Aromatase inhibition leading to reproductive 
dysfunction 
Aromatase Inhibition Reproductive 
dysfunction 
OECD 1.12 
ID: 25 
Oestrogen receptor antagonism leading to 
reproductive dysfunction 
Binding to the oestrogen 
receptor  
Reproductive 
dysfunction 
OECD 1.12 
ID: 30 
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Chronic binding of antagonist to N-methyl-D-
aspartate receptors (NMDARs) during brain 
development leads to neurodegeneration with 
impairment in learning and memory in aging 
Binding to NMDAR Neuroinflammation 
leading  to 
neurodegeneration 
OECD 1.13 
ID: 12 
Chronic binding of antagonist to N-methyl-D-
aspartate receptors (NMDARs) during brain 
development induces impairment of learning and 
memory abilities 
Binding to NMDAR  Impairment of learning 
and memory abilities 
OECD 1.22 
ID: 13 
Aromatase (Cyp19a1) reduction leading to 
impaired fertility in adult female 
Binding to aromatase Impaired fertility OECD 1.21 
ID: 7 
PPARα aĐtiǀatioŶ iŶ utero leadiŶg to iŵpaired 
fertility in males 
Binding to PPAR Impaired fertility OECD 1.21 
ID: 18 
Binding of agonists to ionotropic glutamate 
receptors in adult brain causes excitotoxicity that 
Binding to Glutamate 
Receptor 
Learning and memory 
impairment 
OECD 1.23 
ID: 48 
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mediates neuronal cell death, contributing to 
learning and memory impairment 
Inhibition of the mitochondrial complex I of nigra-
striatal neurons leads to parkinsonian motor 
deficits 
Binding of inhibitor to 
NADH-ubiquinone 
oxidoreductase (complex 
I), 
Motor function, 
impaired 
OECD 1.33 
ID: 3 
    
Acute Enzyme Inhibition 
    
Inhibition of acetylcholinesterase leading to 
lethality 
Irreversible binding to 
acetylcholinesterase 
Lethality 12, 62 
    
Unspecific 
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Reversible membrane disruption leading to 
anaesthesia e.g. non-polar narcosis, basal 
cytotoxicity 
Unspecific membrane 
disruption 
Anaesthesia, lethality 29, 67, 77-78 
    
Physical 
    
Intracellular acidification induced olfactory 
epithelial injury leading to site of contact nasal 
tumours 
Decrease in intracellular 
pH 
contact nasal tumours OECD 2.7 
    
Other 
    
No AOP currently citable on the AOP Wiki 
(although some are in draft form) or available in 
the literature 
   
45 
 
 
46 
 
 
 
Figure 1. Schematic of a generic Adverse Outcome Pathway (from source to ecosystem) with 
the types of in silico models that may be associated with each Key Event. 
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Figure 2. Main differences where models may drive the development of AOPs and vice 
versa. 
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